Abstract:Background Cardiac remodeling predisposes individuals to heart failure if the burden is not solved, and heart failure is a growing cause of morbidity and mortality worldwide. The cardiac extracellular matrix not only provides structural support, but also is a core aspect of the myocardial response to various biomechanical stresses and heart failure. MFAP4 (microfibrillar‐associated protein 4) is an integrin ligand located in the extracellular matrix, whose biological functions in the heart remain poorly understood. In the current study we aimed to test the role of MFAP4 in cardiac remodeling. Methods and Results MFAP4‐deficient (MFAP4 −/− ) and wild‐type mice were subjected to aortic banding surgery and isoproterenol to establish models of cardiac remodeling. We also evaluated the functional effects of MFAP4 on cardiac hypertrophy, fibrosis, and cardiac electrical remodeling. The expression of MFAP4 was increased in the animal cardiac remodeling models induced by pressure overload and isoproterenol. After challenge of 8 weeks of aortic banding or 2 weeks of intraperitoneal isoproterenol, MFAP4 −/− mice exhibited lower levels of cardiac fibrosis and fewer ventricular arrhythmias than wild‐type mice. However, there was no significant effect on cardiomyocyte hypertrophy. In addition, there was no significant difference in cardiac fibrosis severity, hypertrophy, or ventricular arrhythmia incidence between wild‐type‐sham and knockout‐sham mice. Conclusions These findings are the first to demonstrate that MFAP4 deficiency inhibits cardiac fibrosis and ventricular arrhythmias after challenge with 8 weeks of aortic banding or 2 weeks of intraperitoneal isoproterenol but does not significantly affect the hypertrophy response. In addition, MFAP4 deficiency had no significant effect on cardiac fibrosis, hypertrophy, or ventricular arrhythmia in the sham group in this study. Nonstandard Abbreviations and Acronyms AB aortic banding Ad‐shMFAP4 pDKD‐CMV‐eGFP‐U6‐shRNA‐MFAP4 Ad‐shRNA pDKD‐CMV‐eGFP‐U6‐shRNA PCL pacing cycle length MFAP4 microfibrillar‐associated protein 4 VA ventricular arrhythmias Ad‐MFAP4 Adenovirus vector pAdeno‐EF1A(S)‐mNeonGreen‐CMVMfap4‐3FLAG Clinical Perspective What Is New? For the first time we have defined the expression of MFAP4 (microfibrillar‐associated protein 4) was increased in the animal cardiac remodeling models induced by pressure overload and isoproterenol. MFAP4 deficiency inhibits cardiac fibrosis and ventricular arrhythmias after challenge with 8 weeks of aortic banding or 2 weeks of intraperitoneal isoproterenol but does not significantly affect the hypertrophy response. What Are the Clinical Implications? MFAP4 may act as a novel therapeutic target for the upstream prevention of cardiac remodeling and heart failure. Heart failure (HF) is the common ultimate outcome of different types of cardiovascular diseases, and is a growing public health problem associated with high hospitalization and mortality. 1 , 2 , 3 , 4 Cardiac remodeling is an adaptive cellular response to various kinds of biomechanical stresses or hemodynamic overload, that involves a series of structural and functional alterations, including increase in the size and/or thickness of cardiomyocytes and the left ventricle, perivascular and interstitial fibrosis, various types of ventricular and atrial arrhythmias and so on. 5 , 6 Cardiac remodeling predisposes a patient to HF if the burden is not solved, and can be divided into structural remodeling and electrical remodeling. Structural remodeling includes cardiac fibrosis and cardiac hypertroph -Abstract Truncated-

GW27-e0398 Mitogen-activated protein kinase interacting kinase 1 (Mnk1) Deficiency Aggravates Cardiac Remodeling via Regulation of Sprouty2-dependent ERK1/2 pathway

Mnk1 (Mitogen-Activated Protein Kinase-Interacting Kinase 1) Deficiency Aggravates Cardiac Remodeling in Mice

Cardiomyocytes Deficiency of SENP1 Promotes Myocardial Fibrosis Via Paracrine Action

Expression Changes Of Mitogen-Actilvated Protelin Kinase Phosphatase-1 (Mkp-1) In Myocardium Of Streptozotocin-Induced Diabetic Rats

MSK-Mediated Phosphorylation of Histone H3 Ser28 Couples MAPK Signalling with Early Gene Induction and Cardiac Hypertrophy

SGK3 deficiency in macrophages suppresses angiotensin II–induced cardiac remodeling via regulating Ndufa13–mediated mitochondrial oxidative stress

Targeting E3 Ubiquitin-Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination

Myeloid MKL1 Disseminates Cues to Promote Cardiac Hypertrophy in Mice

PFKP inhibition protects against pathological cardiac hypertrophy by regulating protein synthesis

DNA damage and nuclear morphological changes in cardiac hypertrophy are mediated by SNRK through actin depolymerization

SMYD1 modulates the proliferation of multipotent cardiac progenitor cells derived from human pluripotent stem cells during myocardial differentiation through GSK3β/β-catenin&ERK signaling

GRK5 Controls SAP97-Dependent Cardiotoxic β1 Adrenergic Receptor-CaMKII Signaling in Heart Failure

MNK2-eIF4E axis promotes cardiac repair in the infarcted mouse heart by activating cyclin D1

Mep1a contributes to Ang II-induced cardiac remodeling by promoting cardiac hypertrophy, fibrosis and inflammation

Maresin-2 Fine-tunes ULK1 O-GlcNAcylation to Improve Post Myocardial Infarction Remodeling

Microtubule Associated Protein 4 Phosphorylation Leads to Pathological Cardiac Remodeling in Mice.

Role of extracellular signal-regulated kinase 1/2 signaling underlying cardiac hypertrophy

Cardiac tumour necrosis factor receptor-associated factor 7 mediates the ubiquitination of apoptosis signal-regulating kinase 1 and aggravates cardiac hypertrophy

PKM1 Exerts Critical Roles in Cardiac Remodeling Under Pressure Overload in the Heart

Deletion of Microfibrillar-Associated Protein 4 Attenuates Left Ventricular Remodeling and Dysfunction in Heart Failure.

SENP1‐Mediated HSP90ab1 DeSUMOylation in Cardiomyocytes Prevents Myocardial Fibrosis by Paracrine Signaling